BNTX logo

BioNTech SE (BNTX) Cash from operations

annual CFO:

$224.80M-$5.59B(-96.13%)
December 31, 2024

Summary

  • As of today (May 29, 2025), BNTX annual cash flow from operations is $224.80 million, with the most recent change of -$5.59 billion (-96.13%) on December 31, 2024.
  • During the last 3 years, BNTX annual CFO has fallen by -$827.87 million (-78.64%).
  • BNTX annual CFO is now -98.43% below its all-time high of $14.32 billion, reached on December 31, 2022.

Performance

BNTX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

quarterly CFO:

-$821.48M-$308.31M(-60.08%)
March 1, 2025

Summary

  • As of today (May 29, 2025), BNTX quarterly cash flow from operations is -$821.48 million, with the most recent change of -$308.31 million (-60.08%) on March 1, 2025.
  • Over the past year, BNTX quarterly CFO has dropped by -$476.83 million (-138.35%).
  • BNTX quarterly CFO is now -117.21% below its all-time high of $4.77 billion, reached on June 30, 2023.

Performance

BNTX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

TTM CFO:

-$252.02M-$476.83M(-212.11%)
March 1, 2025

Summary

  • As of today (May 29, 2025), BNTX TTM cash flow from operations is -$252.02 million, with the most recent change of -$476.83 million (-212.11%) on March 1, 2025.
  • Over the past year, BNTX TTM CFO has dropped by -$6.45 billion (-104.07%).
  • BNTX TTM CFO is now -101.76% below its all-time high of $14.32 billion, reached on December 31, 2022.

Performance

BNTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherBNTXcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

BNTX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-96.1%-138.3%-104.1%
3 y3 years-78.6%-118.1%-104.2%
5 y5 years+201.2%-1260.9%-2.0%

BNTX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-98.4%at low-117.2%at low-101.8%at low
5 y5-year-98.4%+201.2%-117.2%at low-101.8%+42.0%
alltimeall time-98.4%+201.2%-117.2%at low-101.8%+42.0%

BNTX Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
-$821.48M(+60.1%)
-$252.02M(-212.1%)
Dec 2024
$224.80M(-96.1%)
-$513.17M(-23.7%)
$224.80M(-86.2%)
Sep 2024
-
-$672.46M(-138.3%)
$1.63B(-48.7%)
Jun 2024
-
$1.76B(-609.2%)
$3.18B(-48.7%)
Mar 2024
-
-$344.65M(-138.6%)
$6.20B(+6.6%)
Dec 2023
$5.82B(-59.4%)
$893.27M(+1.8%)
$5.82B(-9.1%)
Sep 2023
-
$877.10M(-81.6%)
$6.40B(-35.2%)
Jun 2023
-
$4.77B(-755.9%)
$9.87B(+9.2%)
Mar 2023
-
-$727.55M(-149.3%)
$9.05B(-36.8%)
Dec 2022
$14.32B(+1260.2%)
$1.48B(-66.1%)
$14.32B(+13.5%)
Sep 2022
-
$4.35B(+10.4%)
$12.61B(+25.6%)
Jun 2022
-
$3.94B(-13.2%)
$10.04B(+68.1%)
Mar 2022
-
$4.54B(-2062.7%)
$5.97B(+467.4%)
DateAnnualQuarterlyTTM
Dec 2021
$1.05B(-6927.8%)
-$231.55M(-113.0%)
$1.05B(-33.2%)
Sep 2021
-
$1.78B(-1572.2%)
$1.58B(-463.0%)
Jun 2021
-
-$120.93M(-67.8%)
-$434.16M(+31.5%)
Mar 2021
-
-$375.12M(-228.6%)
-$330.18M(+2041.6%)
Dec 2020
-$15.42M(-93.1%)
$291.78M(-226.9%)
-$15.42M(-95.9%)
Sep 2020
-
-$229.89M(+1256.4%)
-$379.41M(+86.7%)
Jun 2020
-
-$16.95M(-71.9%)
-$203.27M(-17.7%)
Mar 2020
-
-$60.36M(-16.4%)
-$247.12M(+11.2%)
Dec 2019
-$222.22M(+219.6%)
-$72.21M(+34.4%)
-$222.22M(+48.1%)
Sep 2019
-
-$53.75M(-11.6%)
-$150.01M(+55.8%)
Jun 2019
-
-$60.80M(+71.5%)
-$96.26M(+171.5%)
Mar 2019
-
-$35.46M
-$35.46M
Dec 2018
-$69.52M(+16.8%)
-
-
Dec 2017
-$59.53M
-
-

FAQ

  • What is BioNTech SE annual cash flow from operations?
  • What is the all time high annual CFO for BioNTech SE?
  • What is BioNTech SE annual CFO year-on-year change?
  • What is BioNTech SE quarterly cash flow from operations?
  • What is the all time high quarterly CFO for BioNTech SE?
  • What is BioNTech SE quarterly CFO year-on-year change?
  • What is BioNTech SE TTM cash flow from operations?
  • What is the all time high TTM CFO for BioNTech SE?
  • What is BioNTech SE TTM CFO year-on-year change?

What is BioNTech SE annual cash flow from operations?

The current annual CFO of BNTX is $224.80M

What is the all time high annual CFO for BioNTech SE?

BioNTech SE all-time high annual cash flow from operations is $14.32B

What is BioNTech SE annual CFO year-on-year change?

Over the past year, BNTX annual cash flow from operations has changed by -$5.59B (-96.13%)

What is BioNTech SE quarterly cash flow from operations?

The current quarterly CFO of BNTX is -$821.48M

What is the all time high quarterly CFO for BioNTech SE?

BioNTech SE all-time high quarterly cash flow from operations is $4.77B

What is BioNTech SE quarterly CFO year-on-year change?

Over the past year, BNTX quarterly cash flow from operations has changed by -$476.83M (-138.35%)

What is BioNTech SE TTM cash flow from operations?

The current TTM CFO of BNTX is -$252.02M

What is the all time high TTM CFO for BioNTech SE?

BioNTech SE all-time high TTM cash flow from operations is $14.32B

What is BioNTech SE TTM CFO year-on-year change?

Over the past year, BNTX TTM cash flow from operations has changed by -$6.45B (-104.07%)
On this page